These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15618474)

  • 21. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
    Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
    Cairoli R; Beghini A; Morello E; Grillo G; Montillo M; Larizza L; Morra E
    Leuk Res; 2005 Apr; 29(4):397-400. PubMed ID: 15725473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma.
    Plo I; Lautier D; Casteran N; Dubreuil P; Arock M; Laurent G
    Oncogene; 2001 Oct; 20(46):6752-63. PubMed ID: 11709710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells.
    Scholl S; Kirsch C; Böhmer FD; Klinger R
    J Cancer Res Clin Oncol; 2004 Dec; 130(12):711-8. PubMed ID: 15340843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
    Shafik NF; Ibraheem D; Selim MM; Allam RM; Fathalla LA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e363-e375. PubMed ID: 34972661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.
    Care RS; Valk PJ; Goodeve AC; Abu-Duhier FM; Geertsma-Kleinekoort WM; Wilson GA; Gari MA; Peake IR; Löwenberg B; Reilly JT
    Br J Haematol; 2003 Jun; 121(5):775-7. PubMed ID: 12780793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling.
    Bayle J; Letard S; Frank R; Dubreuil P; De Sepulveda P
    J Biol Chem; 2004 Mar; 279(13):12249-59. PubMed ID: 14707129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.
    Tsujimura T; Morimoto M; Hashimoto K; Moriyama Y; Kitayama H; Matsuzawa Y; Kitamura Y; Kanakura Y
    Blood; 1996 Jan; 87(1):273-83. PubMed ID: 8547652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
    Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
    Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
    Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).
    Blair A; Sutherland HJ
    Exp Hematol; 2000 Jun; 28(6):660-71. PubMed ID: 10880752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.
    Aguilar C; Aguilar C; Lopez-Marure R; Jiménez-Sánchez A; Rocha-Zavaleta L
    Mol Med Rep; 2014 May; 9(5):1895-902. PubMed ID: 24626629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.